Biomedtracker
Biomedtracker is a B2B subscription intelligence platform that tracks clinical and regulatory events across 881 disease indications for pharmaceutical companies, biotech firms, and biotech investors. Operated as part of the Norstella portfolio alongside Evaluate and Datamonitor Healthcare, it provides real-time catalyst tracking, KOL insights, and a 1,993-report intelligence library on annual enterprise subscriptions.
- Company typePrivate
- Founded1999
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Biomedtracker does
Biomedtracker is a B2B subscription intelligence platform that tracks and analyzes clinical and regulatory events for the pharmaceutical and biotech industries. Its core offering is a web-based platform that aggregates and analyzes data on drugs, companies, diseases, clinical trials, regulatory events, and market intelligence across 881 disease indications spanning 20 therapy areas including oncology, neurology, immunology, cardiovascular, metabolic, and rare diseases. The platform provides tools for tracking catalysts, impact events, FDA Advisory Committee meetings, KOL interviews, and market analytics, supplemented by a Report Library of 1,993 reports covering disease analyses, market spotlights, pricing and reimbursement, strategy, conference coverage, and KOL insights. The technology integrates Datamonitor Healthcare content and provides advanced search capabilities across catalysts, companies, drugs, events, deals, FDA AdComm meetings, KOLs, and trial comparisons.
The company is operated by Pharma Intelligence UK Limited and is part of the Norstella portfolio alongside Evaluate, Datamonitor Healthcare, Pharmapremia, and Meddevicetracker. Biomedtracker's go-to-market is enterprise field sales targeting large pharmaceutical companies, biotech firms, and biotech investors/analysts, with direct outreach, demo requests, and a client services team. The platform is accessed via subscription with quote-based annual pricing, and customers can purchase Biomedtracker standalone or as part of cross-product bundles within the Norstella ecosystem.
Biomedtracker's value proposition centers on real-time clinical event tracking, approval likelihood predictions, KOL qualitative insights, and comprehensive market intelligence to support drug pipeline and investment decisions. The platform serves pharmaceutical companies (clinical development strategy, competitive intelligence), biotech investors and analysts (due diligence, pipeline assessment), biotechnology companies (market intelligence), and healthcare consultants (research and analysis). Its marketing approach combines content marketing (report library, disease analyses, KOL publications), event-driven content (ASCO and other major conference coverage), and direct enterprise sales. The company is headquartered in London, UK, and serves a global customer base with primary markets in the US, UK, Germany, and France.
Biomedtracker firmographics
Firmographics- Name
- Biomedtracker
- Legal name
- Pharma Intelligence UK Limited
- Website
- https://biomedtracker.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Biomedtracker is a B2B subscription intelligence platform that tracks clinical and regulatory events across 881 disease indications for pharmaceutical companies, biotech firms, and biotech investors. Operated as part of the Norstella portfolio alongside Evaluate and Datamonitor Healthcare, it provides real-time catalyst tracking, KOL insights, and a 1,993-report intelligence library on annual enterprise subscriptions.
- Ownership category
- akta.pro rank
Biomedtracker industry classification
Industry- Product category
- Pharmaceutical Intelligence Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Biomedtracker is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Biomedtracker business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Subscription Intelligence Services: Biomedtracker operates as a subscription-based SaaS platform providing pharmaceutical intelligence services to enterprise customers. Access to reports, KOL Insight transcripts, and data analytics requires paid subscription. Multiple product tiers exist including Biomedtracker standalone, Datamonitor Healthcare integration, and cross-product access within the Norstella portfolio (Evaluate, Datamonitor Healthcare, Pharmapremia, Meddevicetracker).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription with full platform access |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Biomedtracker product offering
Product offeringCore offering
Biomedtracker is a subscription-based, web-delivered pharmaceutical intelligence platform that provides real-time tracking of drug development catalysts, clinical trial results, regulatory decisions, FDA Advisory Committee activity, and deal events across 881 disease indications. It combines a proprietary impact-event methodology for approval likelihood forecasting with an integrated Report Library of Datamonitor Healthcare disease analyses, market spotlights, KOL interview transcripts, pricing/reimbursement reports, and major conference coverage (ASCO, ESMO, AACR), sold to enterprise pharma, biotech, and investor clients under annual subscription agreements.
Product overview
Biomedtracker is a comprehensive pharma intelligence platform operated by Norstella (Evaluate) that provides real-time tracking and analysis of drug development catalysts, clinical events, regulatory decisions, and deal activity. The platform operates as a unified system with interconnected modules including the core Biomedtracker Platform, Report Library (with Datamonitor Healthcare reports covering Disease Reports, Market Spotlights, PharmaVitae, Pricing & Reimbursement, Strategy, and Conference Reports), Pharma Intelligence Disease Hub (joint coverage with Datamonitor Healthcare across 881 indications), Catalyst Tracking, Impact Events, Deals Intelligence, Regulatory Insights, Advanced Search capabilities, KOL Insight Reports, and Latest Pharma Insights news aggregation. The platform serves pharmaceutical and biotech industry professionals with subscription-based access to intelligence covering companies, drugs, diseases, trials, targets, events, deals, catalysts, and reports.
Differentiator
Problem solved
Functional benefit
Brands
- Datamonitor Healthcare: Healthcare market intelligence reports and disease analysis modules offered within the Biomedtracker platform
Products and services
- Biomedtracker Platform
- Pharma Intelligence Disease Hub Joint coverage platform combining Biomedtracker and Datamonitor Healthcare disease data, providing comprehensive disease intelligence across 881 indications with market spotlights, disease analyses, and forecasts for subscribers.
- Report Library Subscription-accessed collection of healthcare intelligence reports including Datamonitor Healthcare Disease Reports, Market Spotlight Reports, KOL Insight Reports, Conference Reports, PharmaVitae Reports, and Regulatory & Therapeutic Area Reports, covering 1,993 reports across multiple therapy areas.
Companies that use Biomedtracker
Customer profileSegments4 records
Ideal customer profiles3 records
Biomedtracker technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biomedtracker partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NorstellacoreBiomedtracker is a product within the Norstella company portfolio, which includes Evaluate (drug approval tracking and analytics), Datamonitor Healthcare (market intelligence), Pharmapremia (pricing and reimbursement intelligence), and Meddevicetracker (medical device intelligence). Norstella operates Pharma Intelligence UK Limited as the operating entity for Biomedtracker, with integrated cross-product offerings and shared infrastructure.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
Biomedtracker competitors and assessment
Company assessmentDirect peers
- Evaluate (Norstella): Parent company within Norstella and a direct peer offering drug approval tracking, consensus forecasts, and pharma commercial intelligence. Overlapping customer base and product functionality in pharma/biotech intelligence subscriptions.
- Citeline (Pharma Projects): Sister product under Norstella providing drug pipeline intelligence, clinical trial tracking, and regulatory analysis. Directly comparable in pharma intelligence scope and customer base, both serve enterprise pharma and biotech with subscription-based clinical/regulatory intelligence.
- Clarivate (Cortellis): Major pharma intelligence platform offering competitive intelligence, drug pipeline data, patent analytics, and clinical trial insights. Direct competitor in serving pharma R&D and business development teams with subscription intelligence.
- Informa Pharma Intelligence: Historical owner of Biomedtracker and current operator of competing pharma intelligence brands (Scrip, Medtech Insight, HBW Insight). Direct competitor in pharma news, clinical trial, and regulatory intelligence subscriptions.
- GlobalData Pharmaceutical: Provides pharma market intelligence, clinical trial databases, drug pipeline analytics, and epidemiology data. Direct competitor in pharma/biotech subscription intelligence for enterprise customers.
- Adis International: Pharma intelligence publishing brand under Springer Nature providing drug evaluation, clinical trial summaries, and pharmacoeconomic analysis. Comparable in providing subscription-based clinical and commercial intelligence to pharma/biotech.
Emerging players
- AlphaSense: AI-powered market intelligence platform with expanding pharma/biotech content coverage. Emerging competitor using generative AI to disrupt traditional pharma intelligence aggregators like Biomedtracker.
- Definitive Healthcare: Healthcare commercial intelligence provider with overlap in pharma pipeline, clinical development, and healthcare provider analytics. Adjacent competitor for pharma commercial and competitive intelligence use cases.
Broad incumbents
- S&P Capital IQ Pro (Biopharma): Broad financial data platform with biopharma pipeline, clinical trial, and biotech company intelligence modules. Incumbent serving biotech investors and analysts with adjacent product coverage.
- IQVIA (formerly QuintilesIMS): Broad incumbent in pharma services, R&D, and commercial intelligence with extensive data assets overlapping Biomedtracker's clinical trial and market intelligence. Larger portfolio player with broader scope.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Biomedtracker social profiles
Digital presenceBiomedtracker financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biomedtracker leadership team
Management profileNumber of profiles
Biomedtracker funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biomedtracker M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biomedtracker
What does Biomedtracker do?
Biomedtracker is a subscription-based, web-delivered pharmaceutical intelligence platform that provides real-time tracking of drug development catalysts, clinical trial results, regulatory decisions, FDA Advisory Committee activity, and deal events across 881 disease indications. It combines a proprietary impact-event methodology for approval likelihood forecasting with an integrated Report Library of Datamonitor Healthcare disease analyses, market spotlights, KOL interview transcripts, pricing/reimbursement reports, and major conference coverage (ASCO, ESMO, AACR), sold to enterprise pharma, biotech, and investor clients under annual subscription agreements.
Is Biomedtracker a public or private company?
Biomedtracker is a private company. It is classified as corporate owned and is currently operating.
When was Biomedtracker founded?
Biomedtracker was founded in 1999. It employs 1 to 10 people.
Where is Biomedtracker based?
Biomedtracker is headquartered in London, United Kingdom, in the Europe region.
How does Biomedtracker make money?
One revenue line is on record: subscription Intelligence Services.
Who are Biomedtracker's main competitors?
Direct peers on record are Evaluate (Norstella), Citeline (Pharma Projects), Clarivate (Cortellis), Informa Pharma Intelligence, GlobalData Pharmaceutical and Adis International. Emerging players are AlphaSense and Definitive Healthcare. Broad incumbents are S&P Capital IQ Pro (Biopharma) and IQVIA (formerly QuintilesIMS).
Does Biomedtracker have an API?
No public API is recorded for Biomedtracker.
What industry is Biomedtracker in?
Biomedtracker's product category is Pharmaceutical Intelligence Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.